The EU-AIMS Longitudinal European Autism Project (LEAP): Design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders
MetadataShow full item record
Â© 2017 The Author(s). Background: The tremendous clinical and aetiological diversity among individuals with autism spectrum disorder (ASD) has been a major obstacle to the development of new treatments, as many may only be effective in particular subgroups. Precision medicine approaches aim to overcome this challenge by combining pathophysiologically based treatments with stratification biomarkers that predict which treatment may be most beneficial for particular individuals. However, so far, we have no single validated stratification biomarker for ASD. This may be due to the fact that most research studies primarily have focused on the identification of mean case-control differences, rather than within-group variability, and included small samples that were underpowered for stratification approaches. The EU-AIMS Longitudinal European Autism Project (LEAP) is to date the largest multi-centre, multi-disciplinary observational study worldwide that aims to identify and validate stratification biomarkers for ASD. Methods: LEAP includes 437 children and adults with ASD and 300 individuals with typical development or mild intellectual disability. Using an accelerated longitudinal design, each participant is comprehensively characterised in terms of clinical symptoms, comorbidities, functional outcomes, neurocognitive profile, brain structure and function, biochemical markers and genomics. In addition, 51 twin-pairs (of which 36 had one sibling with ASD) are included to identify genetic and environmental factors in phenotypic variability. Results: Here, we describe the demographic characteristics of the cohort, planned analytic stratification approaches, criteria and steps to validate candidate stratification markers, pre-registration procedures to increase transparency, standardisation and data robustness across all analyses, and share some 'lessons learnt'. A clinical characterisation of the cohort is given in the companion paper (Charman et al., accepted). Conclusi on: We expect that LEAP will enable us to confirm, reject and refine current hypotheses of neurocognitive/neurobiological abnormalities, identify biologically and clinically meaningful ASD subgroups, and help us map phenotypic heterogeneity to different aetiologies.
Showing items related by title, author, creator and subject.
Charman, T.; Loth, E.; Tillmann, J.; Crawley, D.; Wooldridge, C.; Goyard, D.; Ahmad, J.; Auyeung, B.; Ambrosino, S.; Banaschewski, T.; Baron-Cohen, S.; Baumeister, S.; Beckmann, C.; Bolte, Sven; Bourgeron, T.; Bours, C.; Brammer, M.; Brandeis, D.; Brogna, C.; De Bruijn, Y.; Chakrabarti, B.; Cornelissen, I.; Acqua, F.; Dumas, G.; Durston, S.; Ecker, C.; Faulkner, J.; Frouin, V.; Garcés, P.; Ham, L.; Hayward, H.; Hipp, J.; Holt, R.; Isaksson, J.; Johnson, M.; Jones, E.; Kundu, P.; Lai, M.; D'Ardhuy, X.; Lombardo, M.; Lythgoe, D.; Mandl, R.; Mason, L.; Meyer-Lindenberg, A.; Moessnang, C.; Mueller, N.; O'Dwyer, L.; Oldehinkel, M.; Oranje, B.; Pandina, G.; Persico, A.; Ruggeri, B.; Ruigrok, A.; Sabet, J.; Sacco, R.; Cáceres, A.; Simonoff, E.; Toro, R.; Tost, H.; Waldman, J.; Williams, S.; Zwiers, M.; Spooren, W.; Murphy, D.; Buitelaar, J. (2017)Â© 2017 The Author(s). Background: The EU-AIMS Longitudinal European Autism Project (LEAP) is to date the largest multi-centre, multi-disciplinary observational study on biomarkers for autism spectrum disorder (ASD). The ...
Recent Advances in Resting-State Electroencephalography Biomarkers for Autism Spectrum Disorder-A Review of Methodological and Clinical ChallengesHeunis, T.; Aldrich, Chris; de Vries, P. (2016)© 2016 Elsevier Inc.Background: Electroencephalography (EEG) has been used for almost a century to identify seizure-related disorders in humans, typically through expert interpretation of multichannel recordings. Attempts ...
Bölte, Sven; Marschik, P.; Falck-Ytter, T.; Charman, T.; Roeyers, H.; Elsabbagh, M. (2013)Currently, autism cannot be reliably diagnosed before the age of 2 years, which is why longitudinal studies of high-risk populations provide the potential to generate unique knowledge about the development of autism during ...